Memantine Improves Cognitive Function and Alters Hippocampal and Cortical Proteome in Triple Transgenic Mouse Model of Alzheimer’s Disease

다국어 초록 (Multilingual Abstract)

Memantine is a non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonist clinically approved for moderate-to-severe Alzheimer’s disease (AD) to improve cognitive functions. There is no report about the proteomic alterations induced by memantine in AD mouse model yet. In this study, we investigated the protein profiles in the hippocampus and the cerebral cortex of AD-related transgenic mouse model (3×Tg-AD) treated with memantine. Mice (8-month) were treated with memantine (5 mg/kg/bid) for 4 months followed by behavioral and molecular evaluation. Using step-down passive avoidance (SDA) test, novel object recognition (NOR) test and Morris water maze (MWM) test, it was observed that memantine significantly improved learning and memory retention in 3xTg-AD mice. By using quantitative proteomic analysis, 3301 and 3140 proteins in the hippocampus and the cerebral cortex respectively were identified to be associated with AD abnormalities. In the hippocampus, memantine significantly altered the expression levels of 233 proteins, among which PCNT, ATAXIN2, TNIK, and NOL3 were up-regulated, and FLNA, MARK 2 and BRAF were down-regulated. In the cerebral cortex, memantine significantly altered the expression levels of 342 proteins, among which PCNT, PMPCB, CRK, and MBP were up-regulated, and DNM2, BRAF, TAGLN 2 and FRY1 were down-regulated. Further analysis with bioinformatics showed that memantine modulated biological pathways associated with cytoskeleton and ErbB signaling in the hippocampus, and modulated biological pathways associated with axon guidance, ribosome, cytoskeleton, calcium and MAPK signaling in the cerebral cortex. Our data indicate that memantine induces higher levels of proteomic alterations in the cerebral cortex than in the hippocampus, suggesting memantine affects various brain regions in different manners. Our study provides a novel view on the complexity of protein responses induced by memantine in the brain of AD.

참고문헌 (Reference)

1 Matenia D, "The tau of MARK : a polarized view of the cytoskeleton" 34 : 332-342, 2009

2 Rudy CC, "The role of the tripartite glutamatergic synapse in the pathophysiology of Alzheimer's disease" 6 : 131-148, 2015

3 Katz JD, "Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors" 27 : 114-120, 2017

4 Ahmed MM, "Protein profiles associated with context fear conditioning and their modulation by memantine" 13 : 919-937, 2014

5 Deng SS, "Protein kinase A rescues microtubule affinity-regulating kinase 2-induced microtubule instability and neurite disruption by phosphorylating serine 409" 290 : 3149-3160, 2015

6 Matenia D, "Microtubule affinity-regulating kinase 2(MARK2)turns on phosphatase and tensin homolog(PTEN)-induced kinase 1(PINK1)at Thr-313, a mutation site in Parkinson disease : effects on mitochondrial transport" 287 : 8174-8186, 2012

7 Chen YM, "Microtubule affinity-regulating kinase 2 functions downstream of the PAR-3/PAR-6/atypical PKC complex in regulating hippocampal neuronal polarity" 103 : 8534-8539, 2006

8 Song MS, "Memantine protects rat cortical cultured neurons against beta-amyloidinduced toxicity by attenuating tau phosphorylation" 28 : 1989-2002, 2008

9 Alley GM, "Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice" 88 : 143-154, 2010

10 Scholtzova H, "Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging" 86 : 2784-2791, 2008

11 Reisberg B, "Memantine in moderate-to-severe Alzheimer's disease" 348 : 1333-1341, 2003

12 Martinez-Coria H, "Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice" 176 : 870-880, 2010

13 Wang X, "Memantine attenuates Alzheimer's disease-like pathology and cognitive impairment" 10 : e0145441-, 2015

14 Johnson JW, "Mechanism of action of memantine" 6 : 61-67, 2006

15 Drewes G, "MARKing tau for tangles and toxicity" 29 : 548-555, 2004

16 Bernard LP, "MARK/Par 1 kinase is activated downstream of NMDA receptors through a PKA-dependent mechanism" 10 : e0124816-, 2015

17 Drewes G, "MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption" 89 : 297-308, 1997

18 Marvanová M, "Identification of genes regulated by memantine and MK-801 in adult rat brain by cDNA microarray analysis" 29 : 1070-1079, 2004

19 Zhou X, "Hippocampal proteomic alteration in triple transgenic mouse model of Alzheimer's disease and implication of PINK 1regulation in donepezil treatment" 18 : 1542-1552, 2019

20 Matenia D, "Emerging modes of PINK1 signaling : another task for MARK2" 7 : 37-, 2014

21 Gu GJ, "Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease" 33 : 699-713, 2013

22 Di Iorio G, "Efficacy of memantine in schizophrenic patients : a systematic review" 2017 : 2017

23 Sekiguchi K, "Effects of memantine on the growth and protein profiles of neuroblastoma cells" 5 : 1-8, 2018

24 Lee VM, "Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets" 1 : a006437-, 2011

25 Yiannopoulou KG, "Current and future treatments for Alzheimer's disease" 6 : 19-33, 2013

26 Nagakura A, "Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine" 703 : 53-61, 2013

27 De Felice FG, "Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptordependent mechanism that is blocked by the Alzheimer drug memantine" 282 : 11590-11601, 2007

28 Danysz W, "Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections" 167 : 324-352, 2012

29 Du X, "Alzheimer's disease hypothesis and related therapies" 7 : 2-, 2018